Ability Protect Proprietary Technology Vital Business Uncertain Accelerated Share Repurchase Agreement
Acceptable Underwriter Furnished Respective Opinions Dated Closing Date Acceptance Ubss Offer Relating Auction Rate Securities
Accountability Training Accounting Pronouncements Issued Not Yet Adopted
Accrued Expenses Acquisition Indevus Pharmaceuticals Inc
Acquisitions Acquisitions License Collaboration Agreements
Actions Taken Significant Stockholders Divert Time Attention Board Additional Products
Adjustment Change Capitalization Administration Plan
Administrative Agent Adopted 2007
Adoption Fsp Apb 14-1 Adverse Recommendation Change
Affiliate Age Discrimination Employment Act
Aggregated Option Exercises Last End Values Agreement
Agreement Plan Merger Agreements Agrees Several Underwriters
Alexza Pharmaceuticals Inc Alkermes
Allergan Esprit Almac Pharma Services
Also Promotes David Kerr Head Commercial Business Alterations Improvements
Although Successful Patent Challenge Against Purdue Generic Oxycontin Amended Restated Employment Agreement
Amendment Amendment Amended Restated Certificate Incorporation
Amendment Lease Amendment License Supply Agreement
Amendment Termination Plan Amendments
Amendments Supplements Waivers Anda Process
Annual Base Rent Annual Meeting Admission
Annual Report 2005 Annual Report 2006
Annual Report 2007 Annual Report Form 10-k
Appointment David Holveck Appointment Ivan Gergel
Appointment New Outside Director Board Approval 2007 Stock Incentive Plan
Assignment Form Assignment Sublet
Attestation Report Independent Registered Public Accounting Firm Audit Committee
Audit Committee Financial Experts Audit Committee Report
Audits Taxes Payment Currency Other Terms Aurigene Discovery Technologies Limited
Authorities Authority
Authority Composition Authorized Capital Stock
Availability Party Reimbursement Products Uncertain Thus Find Difficult Available Information
Aveed Aveed Testosterone Undecanoate Injection
Base Salary Basic Compensation
Basic Diluted Loss Per Share Basis Presentation
Bayerschering Bayerschering Pharma
Beneficial Ownership Reporting Compliance Benefit Agreements
Benefit Plans Benefits Perquisites
Bioniche Life Sciences Inc Bml Pharmaceuticals
Board Board Directors
Board Directors Recommends Vote Election Nominees Board Directors Recommends Vote Proposed Amendment Endo Pharmaceuticals
Boxed Warning Branded Business Activity
Branded Products Breakthrough Cancer Pain
Bulk Narcotics Raw Materials Business Environment
Calculation Registration Fee Catalent Pharma Solutions Inc
Caution Readers Prospectus Accompanying Supplement Not Place Undue Cautionary Regarding Forward-looking Statements
Cercla Certain Circumstances Lose Potential Receive Future Royalty Payments
Certain Federal Tax Consequences Non-us Holders Common Stock Certain Relationships Related Transactions
Certificate Incorporation Certificate Merger
Cervelo Pharmaceuticals Chadds Ford New York 2008
Chadds Ford Pennsylvania Change Executives Directors
Changes Directors Officers Changes Directors Officers Other Related Matters
Changes Internal Control Over Financial Reporting Chargebacks
Charles Rowland Chief Financial Officer Charles Rowland Resignation
Chief Operating Officer Chronogesic Clinical Development Programs
Cleanup Closing
Closing Date Co-promotion Agreement
Code Code Conduct
Code Ethics Collaboration Agreements
Collaboration Partners Meet Obligations Pursuant Various Agreements Material Commercial Products
Commitments Commitments Contingencies
Committees Board Directors Related Reports Common Stock
Common Stock Outstanding Common Stock Ownership Guidelines
Comparative Year-to-date Results Compared 2003
Compared 2004 Compared 2005
Compared 2006 Compared 2006 Net Sales
Compensation Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report Executive
Compensation Components Compensation Fees Payable Vcs
Compensation Funded Endo Pharma Llc Compensation Related Stock Options Endo Pharma Llc Option
Compensation Related Stock Options Endo Pharmaceuticals Holdings Inc Competition
Competitive Considerations Competitive Strengths
Completion Acquisition Assets Composition Board Directors Change Near-term
Composition Board Directors Recently Changed Continue Change Near-term Composition Committee
Comprehensive Income Conditions
Conference Call Information Confidential
Confidential Portions Been Filed Separately Securities Exchange Pursuant Confidential Treatment Requested
Confidentiality Confidentiality Agreement
Confidentiality Party Communication Consent Independent Registered Public Accounting Firm
Consideration Payments Consolidated Balance Sheets
Consolidated Financial Statements Impacted Future Periods Based Accuracy Consolidation Merger Binding Share Exchange Conveyance Transfer Lease
Contingencies Contingent Cash Consideration Agreements
Contingent Stock Rights Agreement Continuing Sales Endo Pharma Llc Result Changes Composition
Contract Controls Procedures
Conversion Notice Convertible Debt Offering
Convertible Hedge Warrant Transactions Convertible Notes
Convertible Notes Due 2009 Convertible Senior Subordinated Notes Due 2015
Core Product Cost Proxy Solicitation
Cost Sales Gross Margin Costs Expenses Tenant Assumed Duties Defined Paragraph Additional
Covenants Covenants Tenant
Creation Direct Financial Obligation Off-balance Sheet Arrangement Credit Agreement Limits Ability Conduct Business Negatively Affect
Credit Facility Critical Accounting Estimates
Critical Accounting Estimates Application Policies Critical Accounting Policies Estimates
Current Report Date Prospectus
Dated Closing Date Addressed Underwriter Substantially Form Attached Dea Limits Availability Active Ingredients Used Current Products
Deductibility Cap Executive Compensation Policy Parachute Payments Deferred Stock Units
Definition Consolidated Ebitda Definitions
Demised Premises Department Health Human Services Subpoena
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Dependent Outside Manufacturers Manufacture Products Therefore Limited Control Description Amendment Vote Required
Description Business Description Credit Facility
Detailing Targets Development Licensed Product New Indications
Director Not Standing Re-election Directors
Directors Liability Disclosure Controls Procedures
Disclosure Letter Dissenters Rights
Dissenting Shares Dividend Policy
Dividends Documents Filed Part Annual Report Form 10-k
Documents Incorporated Reference Dollars
Draft Drug Enforcement Administration
Durect Corporation Duties
Duties Responsibilities Committee Each Selling Stockholder Severally Not Jointly Agrees Several
Each Selling Stockholder Severally Not Jointly Represents Warrants Earnings Per Share
Earnings Per Share Guidance Eferred Stock
Effect Change Control Effective Time
Efforts Manufacturers Branded Pharmaceuticals Litigation Legislative Regulatory Means Eligibility
Emea Employee Stock Option Plans
Employees Employment Agreement
Employment Agreements Employment Agreements Named Executive Officers
Employment Agreements Termination Change-in-control Arrangements Employment Change Control Agreements Severance
Employment Terms Duties Endo
Endo Announces Changes Corporate Board Endo Announces Resignation Board Member
Endo Companies Public Announcement Endo Pharma Llc 1997 Executive Employee Stock Option
Endo Pharmaceuticals Endo Pharmaceuticals Announces Resignation Chief Financial Officer
Endo Pharmaceuticals Announces Resignation Chief Operating Officer Endo Pharmaceuticals Appoints Nancy Hutson Board Directors
Endo Pharmaceuticals Appoints William Montague Board Directors Endo Pharmaceuticals Completes Acquisition Indevus
Endo Pharmaceuticals Holdings Inc Endo Pharmaceuticals Holdings Inc 2000 2004 2007 Stock
Endo Pharmaceuticals Holdings Inc 2000 2004 Stock Incentive Endo Pharmaceuticals Holdings Inc Announces Stock Repurchase Program
Endo Pharmaceuticals Holdings Inc Registration Statement Form S-3 Endo Pharmaceuticals Lectec Settle Patent Dispute
Endo Pharmaceuticals Provides Update Developmental Transdermal Fentanyl Patch Endocentive Stock Award Agreement
Entered Tax Sharing Agreement Endo Pharma Llc 2000 Entity
Entry Amendment Material Definitive Agreement Entry Material Definitive Agreement
Environmental Laws Environmental Matters
Environmental Permits Epicept Corp
Equity Compensation Plan Information Equity Compensation Plans Not Approved Security Holders
Erson Escalation
Espp Esprit Pliva
Estoppel Certificate European Economic Area
Evaluation Committee Evaluation Disclosure Controls Procedures
Event Ubs Becomes Insolvent Not Meet Obligations Rights Events Default
Exact Name Registrant Specified Charter Except Per Share Data
Exchange Act Exchange Agent
Exchange Fund Executive Deferred Compensation Plan
Executive Officers Executive Officers Registrant
Executive Vice President Research Development Exhibits
Experts Explanatory
Exposed Risks Unable Comply Changes Laws Affecting Public Face Intense Competition Brand-name Companies Sell License Own
Face Intense Competition Other Manufacturers Generic Versions Products Face Intense Competition Particular Companies Develop Rival Products
Facilities Expenses Fair Value
Falsification Sample Documents Fda
Fdca Federal Estate Tax
Federal Income Tax Consequences 2007 Stock Incentive Plan Fees Paid Independent Registered Public Accounting Firm
Ffect Financial Guidance
Financial Results Financial Statements
Financial Statements Exhibits Find Information
Firpta Certificate Following Discussion Certain Relevant Federal Income Tax Effects
Following Table Sets Forth Costs Expenses 2006 2005 Force Majeure
Foreign Currency Risk Form 10-k
Form 10-q Form Release Agreement
Form S-3 Registration Statement Securities Act 1933 Form Stock Option Grant Agreement
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statement Forward-looking Statement Undertakes Obligation Update Statements Whether Result
Forward-looking Statements Full-year 2005 Financial Results
Full-year 2006 Financial Results Full-year Financial Results
Full-year Financial Results 2007 Full-year Results
Fundamental Change Gaap
Gain Disposal Common Stock Gain Extinguishment Debt
General General Information
General Information Voting Required Vote General Provisions
Generic Manufacturers Litigation Regulatory Means Obtain Approval Versions Generic Non-promoted Products
Generic Products Good Clinical Practices
Good Laboratory Practices Good Manufacturing Practices
Goodwill Intangible Assets Goodwill Other Intangibles
Government Benefit Programs Governmental Entity
Governmental Regulation Grant
Gross Margin Costs Expenses Growth Development Depend Developing Commercializing Marketing New Products
GrĂ¼nenthal Gmbh Guarantees
Guidance Harvard University
Hazardous Substances Headings Part Lease
Held 2006 Held 2007
Held 2008 Held 2009
Helsinn Chemicals Advanced Synthesis Highlights
Hind Healthcare Inc Holding Operations
Hsr Act Hydron Polymer Technology
Hydron Technologies Inc Impairment Other Intangible Assets
Impeding Event Important Information Frova
Important Safety Information Improvement Demised Premises
Income Tax Income Taxes
Incorporation Certain Documents Reference Incur Liability Continuing Medical Health Education Programs Product
Incur Significant Liability Determined Promoting Off-label Drugs Ind
Indemnification Indemnification Directors Officers
Indemnitors Default Obligations Outcome Redux Litigation Materially Harm Indemnity Product Liability
Indenture Independent Contractor
Independent Directors Independent Outside Director
Independent Registered Public Accounting Firm Indevus Acquisition
Indevus Pharmaceuticals Inc Indevus Tender Offer
Index Index Exhibits
Index Financial Statements Index Form 10-k
Industry Inflation
Inflation Not Believe Had Material Adverse Effect Financial Influenced Significant Shareholder Whose Interests Not Aligned Other
Influenced Significant Shareholder Whose Interests Not Always Aligned Information Reporting Backup Withholding Tax
Initial Purchasers Exercise Overallotment Option Insurance
Insurance Requirements Intellectual Property
Interest Expense Interest Expense Income Net
Interest Other Income Interest Other Income Net
Interest Rate Risk Interests Certain Directors
Internal Control Over Financial Reporting Inventories
Inventories Net Invest Securities Subject Market Risk Recent Issues Financial
Investigations Studies Outside Advisers Investment New Therapeutic Areas
Investment Risk Investors
Iquidity Capital Resources Judgments
Ketoprofen Patch Kindly Request Not Include Comments Questions Form Delay
Known Laboratories Inc County Washington Abbott Wayne Westchester Yates
Landlords Environmental Clause Landlords Rights
Lavipharm Lavipharm Laboratories Inc
Law Lease Agreement
Lease Amendment Lease Contains Agreements
Leases Lectec Corporation Chattem Inc
Ledgemont Pharma Secured Notes Legal Matters
Legal Proceedings Les Laboratories Servier
Letterhead Endo Pharma Llc Officer Director Pharmaceuticals Holdings License Agreements Milestones Royalties
License Collaboration Agreements Licensed
Lidoderm Liens
Life Sciences Opportunities Fund Institutional Lilly
Linda Serafin Purdue Pharma 103031 Supreme Court State Line Extensions Non-compete
Liquidity Liquidity Capital Resources
List Schedules List Stockholders
Litigation Long-term Equity-based Incentive Compensation
Long-term Incentive Compensation Low Testosterone
Machinery Weights Locks Insurance Risks Madaus
Major Customers Mallinckrodt Inc
Managements Report Internal Control Over Financial Reporting Manhattan Pharmaceuticals
Manufacturing Supply Other Service Agreements Marketable Securities
Material Adverse Effect Maximum Supply Capacity
Medical Research Council Meeting
Meetings Committee Meetings Included Agreement
Meetings Procedures Committee Merger
Merger Consideration Merger Sub
Merger Sub Common Stock Message Only Form Confirmation Dispatched Please Execute Return
Milestones Royalties Miscellaneous
Monthly Sample Reconciliation Most Net Sales Come Small Number Products
Mrc Name Address Common Stock Transfer Agent
Name Person Filing Proxy Statement Other Registrant Name Registrant Specified Charter
Nasdaq Nature Business
Nda Nda Process
Nebido Nebido Transition Team
Neither Securities Exchange Nor State Approved Disapproved Passed Net Cash Used Financing Activities
Net Income Per Share Net Sales
New Hire Information Package New Plan
New Plan Benefits New Research Development Priorities
News Release Nominating Committee
Nominating Governance Committee Nominees
Nominees Directors Non-competition Non-interference
Non-disclosure Covenant Non-gaap Measures Adjusted Net Income Diluted Earnings Per
Non-gaap Measures Consolidated Ebitda Adjusted Net Income Diluted Non-gaap Measures-adjusted Net Income Adjusted Diluted Earnings Per
Non-recourse Notes Non-solicitation Employees
Nonqualified Deferred Compensation Plan Not Able Maintain Current Insurance Policies Covering Business
Not Applicable Not Paid Pay Dividends Therefore Unless Stock Appreciates
Notes Consolidated Financial Statements Notice Adverse Recommendation
Notices Notification Client Fda Reportable Events
Novartis Novartis Consumer Health Inc
Noven Pharmaceuticals Inc Novexel
Novopharm Limited Octreotide
Offer Offer Closing Date
Offer Conditions Offer Documents
Offer Price Offering
Officers Offices
Once Approved Guarantee Market Accept Future Products Regulatory Oncology Endocrinology Products
Only Respect Director Following Applies Include Only Respect Endo Pharma Llc Include
Only Respect Officer Director Include Opana
Operations Disrupted Information Systems Fail Unsuccessful Implementing Necessary Option
Options Exercised Stock Vested 2006 Options Exercises 2007
Options Exercises Stock Vested 2007 Options Exercises Stock Vested 2008
Options Outstanding Order
Orexo Organizational Documents
Orion Corporation Osteoarthritis
Otc Switch Rights Other
Other Also Undisclosed Products Therapeutic Areas Interest Early Other Balance Branded Portfolio Consists Number Products Accounted
Other Branded Products Other Collaboration Agreements
Other Events Other Expense Income Net
Other Expense Net Other Expenses Issuance Distribution
Other Fda Matters Other Income Net
Other Information Other Legal Proceedings
Other Long-term Liabilities Other Matters
Other Rights Other Sales Deductions
Other Stock Award Grants Outcome Redux Litigation Materially Harm
Outlook Outside Consultants
Overall Program Objectives Oversight Annual Audit Quarterly Reviews
Oversight Financial Reporting Process Internal Controls Overview
Overview Auction-rate Securities Overview Auction-rate Securities Rights
Ownership Guidelines Executive Management Ownership Guidelines Non-employee Directors
Ownership Property Developments Oxycodone Litigation
Oxymorphone Pain Products
Paligent Inc Paragraph Certifications Opana
Paragraph Certifications Opana Facetimes New Roman Size1 Paragraph Certifications Sanctura
Parent Parent Filed Sec Report
Parent Sec Reports Part
Party Expert Dispute Resolution Procedures Party Manufacturing Supply Other Service Agreements
Patent Lawsuit Endo Pharmaceuticals Patent License Agreement
Patent Litigation Often Time-consuming Expensive Material Adverse Effect Patent Non-patent Exclusivity Periods
Patents Trademarks Licenses Proprietary Property Payment Interest Additional Shares
Payments Endo Pharma Llc Carol Ammon Payments Endo Pharma Llc Certain Named Executive Officers
Pension Plans Penwest Pharmaceuticals
Per Share Paid Value Performace Share Award
Performance Graph Performance-based Annual Cash Incentive Compensation
Permits Peter Lankau Resignation
Peter Lankau Resignation Appointment David Holveck Pharmaceutical Industry Heavily Regulated Creates Uncertainty Ability Bring
Pharmacovigilance Pipeline Developments
Pipeline Update Plan Distribution
Plantex Population Council
Positive Outcome Also Reported Immediate-release Oxymorphone Trial Possession
Post-termination Benefits Power Attorney
Ppd Development Pre-approval Policy
Pre-merger Endo Warrants Preferred Stock
Prescriber Signature Verification Program Press Release Contains Information Includes Based Forward-looking Statements
Previously Reported Case Pending Chancery Court Hinds County Previously Reported Case Pending Circuit Court Montgomery County
Pricing Litigation Primary Executives
Pro Forma Adjustments Pro Forma Condensed Consolidated Financial Statements Endo Pharmaceuticals
Proceeds Product Information
Product Listing Pricing Schedule Product Overview
Product Review Products
Products Contract Products Development
Proethic Pharmaceuticals Inc Properties
Property Equipment Property Plant Equipment
Propofol Idd-d Prospectus
Provisions Redacted Proxy Statement
Publication Negative Results Studies Clinical Trials Adversely Impact Purchase Agreement
Purchase Sale Purdue Companies
Purdue Companies Public Announcement Purdue Pharma Announces Resolution Oxycontin Patent Lawsuit
Purpose Committee Purposes
Pursuant Securities Exchange Act 1934 Quality Assurance Requirements
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Data
Raises 2008 Guidance Reasons Effects Proposed Amendment
Rebates Recalls
Receivable Recent Accounting Pronouncements
Recent Developments Recently Adopted Accounting Pronouncements
Recitals Reconciling
Record Retention Retrieval Recovery Compensation
Red Employees References
Refocused Sales Marketing Programs Registrants Telephone Number Including Area Code 610 558-9800
Registration Settlement Private Placement Regulation Disclosure
Regulatory Affairs Regulatory Approval Process Outside Varies Depending Foreign Requirements
Regulatory Authority Regulatory Authorizations
Related Party Transactions Relationships
Release Remedies Cumulative
Removal Goods Report Independent Registered Public Accounting Firm
Reporting Payment Obligations Medicaid Rebate Program Other Governmental Representations Parties
Representations Warranties Representatives
Requisite Short-form Merger Shares Research Contracts
Research Development Responsibilities Endo Management
Responsibility Landlord Restoration Plan
Restricted Stock Restricted Stock Awards
Restricted Stock Units Restructuring
Results Include Record Quarterly Nine-months Net Sales Results Operation Financial Condition
Results Operations Results Operations 2006
Results Operations Financial Condition Retirement Benefits Not Effect Executive Programs Employment Change
Returns Revenue Recognition
Revenues Operating Results Fluctuate Future Periods Fail Meet Review
Review Approval Transactions Related Persons Revised Eps Guidance
Revised Financial Guidance Revised Guidance
Revised Operating Model Revoke Change Vote
Right Negotiation Rights Liquidation
Risk Factors Risks Associated Recent Acquisition Indevus Pharmaceuticals Inc Including
Risks Related Business Roger Kimmel Appointed Chairman
Roles Responsibilities Compensation Committee Royalties
Royalties Allergan Agreement Not Sufficient Subsidiary Meet Payment Rules Regulations
Rxkinetix Acquisition Rxkinetix Inc
Safe Harbor Statement Sale Competing Product Employment Vcs Field Force After
Sales Deductions Sales Products Adversely Affected Consolidation Wholesale Drug Distribution
Sales Representative Services Agreement Sample Accountability Reporting
Sample Distribution Sample Inventory Audits
Samples Lost Transit Sanofi-aventis
Sarbanes-oxley Act Satisfaction Discharge
Savient Savings Investment Plan
Savings Investment Plan Deferred Compensation Plans Schedule
Schedule 14d-9 Schedule 402
Schedule Exchanges Securities Schedules
Scope Services Professionalism Compliance Seasonality
Sec Report Sec Reports
Secondary Offering Common Stock Secretary
Sections Securities Exchange Act 1934 Securities Act
Securities Exchange Act 1934 Securities Registered Pursuant Act
Securities Shall Been Duly Approved Quotation Nasdaq National Security Deposit
Selected Product Review Selection Evaluation Auditors
Selection Evaluation Independent Registered Public Accountants Service Agreements
Settlement Agreement Settlement Oxycontin Patent Case
Severe Pain Patients Share Repurchase Program
Shares Available Awards Sharp Corporation
Shire Pharmaceuticals Group Plc Signature
Signature Page Follows Signatures
Significant Goodwill Other Intangible Assets Consequently Potential Impairment Significant Loss Drug Samples
Significant Number Indevus Stockholders Validly Assert Appraisal Rights Signs
Size1 Skyepharma Inc
Source Wolters Kluwer Healths Phast Prescription Audit Trxs State License Validation
Stock Stock Incentive Plan
Stock Incentive Plans Options Outstanding Stock Option Plan Modifications
Stock Option Sar Grants Last Stock Options
Stock Plans Stock Price Volatile Investment Common Decline Value
Stock Rights Stock-based Compensation
Stockholder Approval Stockholder Communications Directors
Stockholder Proposals 2006 Annual Meeting Stockholder Proposals 2008 Annual Meeting
Stockholder Proposals 2009 Annual Meeting Stockholder Proposals 2010 Annual Meeting
Stockholder Tender Agreements Stockholders Entitled Vote
Stockholders Equity Stockholders Sell Substantial Amounts Common Stock Market Price
Stop Selling Infringing Oxycodone Products End 2006 Strakan International Limited
Strategic Alliance Agreement Strategic Focus
Strategy Strong Financial Results
Subject Completion Preliminary Prospectus Supplement Dated 2006 Subject Product Liability Claims Recalls Unable Obtain Maintain
Subject Various Regulations Pertaining Marketing Products Submission Matters Vote Security Holders
Subsequent Accounting Auction-rate Securities Rights Subsequent Events
Subsidiaries Subsidiary
Success Acquisition Licensing Strategy Subject Uncertainty Completed Acquisitions Summary Recent Events
Summary Recent Transactions Superior Proposal
Supernus Supplemental Contingent Stock Rights Agreements
Supplemental Financial Information Supplemental Indenture
Supplemental Octreotide Contingent Stock Rights Agreement Supplemental Stent Contingent Stock Rights Agreement
Supplemental Supprelin Contingent Stock Rights Agreement Surviving Corporation
Tables Attached Takeover Proposal
Takeover Statute Tax Return
Taxes Technology
Teikoku Seiyaku Ltd Term
Termination Termination Agreement
Termination Election Not Renew Termination Employment
Termination Lease Termination Rights Obligations Respect Licensed Product
Teva Teva Pharmaceutical Industries Ltd
Theft Drug Samples Time Essence
Time Place Payment Timing Results Clinical Trials Demonstrate Safety Efficacy Products
Title Top-up Option
Top-up Shares Topical Treatment Relief Osteoarthritis Pain
Total Compensation Transaction Agreements
Transactions Committee Transactions Related Persons Promoters Certain Control
Transfer Agent Registrar Transfer Marketing Materials Trademarks Logos Artwork
Transition Committee Transition Plan
Types Awards Ubs Financial Services Inc
Unable Retain Key Personnel Continue Attract Additional Professional Underwriting
United Kingdom United States
Upcoming Retirement Cfo Jeff Black Update
Update Review Ups Supply Chain Solutions Inc Livingston Healthcare Services
Vacations Holidays Valeant Canada Ltd
Valera Acquisition Validity Securities
Valuation Auction-rate Securities Valuation Auction-rate Securities Rights
Valuation Long-lived Assets Valuation Point
Vcs Field Force District Manager Vcs Field Force Information Report
Vcs Sales Representative Ventiv Commercial Services Llc
Vernalis Development Limited Voltaren Gel
Vote Mail Vote Required
Voting Annual Meeting Voting Other Matters
Voting Rights Warn Act
Warranties Selling Stockholders Agreement True Correct Closing Date Welfare Plans
Westbury New York Withdrawal Redux Legal Proceedings Insurance Claims Related Contingencies
Witnesseth Wwwendocom
Year-to-date Results Zars Pharma
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki